Manipal Hospitals collaborates with Dr Reddy's for Sputnik V vaccine

Manipal Hospitals said it has collaborated with Dr Reddy's Laboratories to add the Sputnik V Covid-19 vaccine in its existing vaccine portfolio that consists of Covishield and Covaxin

Sputnik V
Sputnik V. Photo: Reuters
Press Trust of India New Delhi
2 min read Last Updated : Jun 06 2021 | 12:14 PM IST

Don't want to miss the best from Business Standard?

Sputnik V. Photo: Reuters

Leading hospital chain Manipal Hospitals on Sunday said it has collaborated with Dr Reddy's Laboratories to add the Sputnik V COVID-19 vaccine in its existing vaccine portfolio that consists of Covishield and Covaxin.

The roll-out of the Sputnik V vaccine by Manipal Hospitals in Bengaluru is part of the limited pilot soft launch initiated by Dr Reddy's in Hyderabad last month, Manipal Hospitals said in a statement.

"Manipal Hospitals has worked closely with Dr Reddy's to create the state-of-the-art infrastructure to maintain Sputnik V vaccine," Manipal Health Enterprises Chief Operating Officer Karthik Rajagopal said.

He added that the hospital chain has successfully conducted vaccination drives with Covishield and Covaxin across the country till date and will continue the efforts along with the new addition of Sputnik V.

Manipal Hospitals expects the vaccine to be available for the public soon in the latter half of the month, Rajagopal said.

"We are pleased to collaborate with Manipal Hospital in Bengaluru as we scale up our soft pilot launch of the Sputnik V vaccine in India and extend it to more cities ahead of the commercial launch later in June.

"In the upcoming months, we hope to inoculate as many Indians as possible," Dr Reddy's Branded Markets (India and Emerging Markets) CEO M V Ramana said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSputnik for sale

First Published: Jun 06 2021 | 12:12 PM IST

Next Story